The International Society of Pharmacoeconomics and Outcomes Research’s Value in Health earlier this week announced a new study focused on achieving “reasonable drug cost estimates for U.S.-based cost-effectiveness analyses.”
According to a press release, the report, “A Transparent and Consistent Approach to Assess U.S. Outpatient Drug Costs for the Use in Cost-Effectiveness Analyses,” was published in Value in Health’s June edition.
The new approach recommends using the National Average Drug Acquisition Cost (NADAC) as the high-end estimate for net drug prices for brand or generic drugs, and the Veterans Affairs Federal Supply Schedule as the lower end.
“Our article provides a clear methodology that improves on current practice to utilize metrics that do not rely on a particular National Drug Code list price,” University of Maryland School of Pharmacy’s Joseph Levy, lead author of the study, said.
